NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus
Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China.
Phase:
NA
Details
Lead Sponsor:
Base Therapeutics (Shanghai) Co., Ltd.
Collaborator:
The First Affiliated Hospital of Anhui Medical University